- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 29.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.01. | NewcelX Ltd.: NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression | 514 | PR Newswire | ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine... ► Artikel lesen | |
| 12.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX: Patent für neurologische Therapien in China veröffentlicht | 4 | Investing.com Deutsch | ||
| 11.12.25 | NewcelX patent for neurological disease treatments published in China | 2 | Investing.com | ||
| 17.11.25 | NewcelX appoints ALS specialist to scientific advisory board | 1 | Investing.com | ||
| 17.11.25 | NewcelX Ltd.: NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute | 169 | PR Newswire | ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
| 17.11.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11.25 | Neurology expert Prof. Ben-Hur joins NewcelX scientific board | 2 | Investing.com | ||
| 04.11.25 | NewcelX Ltd.: NewcelX CEO Issues Letter to Shareholders | 208 | PR Newswire | ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies... ► Artikel lesen | |
| 03.11.25 | NewcelX Ltd.: NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. | 280 | PR Newswire | ZURICH, Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based... ► Artikel lesen | |
| 03.11.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10.25 | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger / Combined Company Re-Named NewcelX Ltd. | 615 | PR Newswire | Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"
ZURICH and NESS ZIONA... ► Artikel lesen | |
| 30.10.25 | NSE/A - NLS Pharmaceutics Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 30.10.25 | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.10.25 | NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger | 713 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system... ► Artikel lesen | |
| 29.10.25 | NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem | 320 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DISC MEDICINE | 56,12 | -21,67 % | Disc Medicine Inc: Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use... ► Artikel lesen | |
| ARCELLX | 68,50 | -0,22 % | Rothschild Redburn downgrades Arcellx stock to Neutral on competition concerns | ||
| QIAGEN | 43,280 | +1,00 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,88 | -0,05 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| UPSTREAM BIO | 8,740 | -31,72 % | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,78 | -3,91 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| ZENAS BIOPHARMA | 26,520 | +1,57 % | Zenas BioPharma's MS drug shows 95% reduction in brain lesions | ||
| EVOTEC | 6,186 | +6,18 % | Bayer, Evotec oder Novo Nordisk: Dieser Biotech setzt zum Sprung an! | Seit Jahren schlagen unsere Aktien-Profis regelmäßig den Gesamtmarkt und sorgen für steile Renditen in den Anlegerdepots. So auch mit den Aktien von Bayer, Evotec oder Novo Nordisk. Doch unser Top-Favorit... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 67,74 | -2,27 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 317,31 | -4,69 % | Guggenheim raises Praxis Precision Medicines stock price target on essential tremor opportunity | ||
| RECURSION PHARMACEUTICALS | 3,495 | -2,37 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,930 | +3,71 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| ERASCA | 12,020 | -2,36 % | Stifel bestätigt Kaufempfehlung für Erasca mit Kursziel von 10 US-Dollar | ||
| MINERALYS THERAPEUTICS | 27,600 | -0,93 % | Mineralys Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TANGO THERAPEUTICS | 12,900 | +1,82 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
NEWCELX LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-0,72 %) liegt der Kurs bei 2,770 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.